Introduction {#sec1}
============

Intervertebral disk herniation is relatively common in dogs ([@ref10]). In dogs, spinal nerves begin somewhere near the fifth lumbar vertebra and travel along the cauda equina. Therefore, disk herniation at the thoracolumbar transition generally causes injury to the spinal cord. The neurologic symptoms associated with canine disk herniation are classified into five stages: pain without other symptoms (Grade 1), ambulatory paresis (Grade 2), non-ambulatory paresis (Grade 3), paraplegia (Grade 4), and paraplegia with loss of pain sensation (Grade 5) ([@ref30]). The severity of symptoms is considered to be dependent on the degree and extent of compression and damage to the spinal cord. Surgical decompression, such as hemilaminectomy, is indicated in cases with severe symptoms, including pain and paralysis. Animals with paresis or those with paraplegia but no loss of pain sensation (Grades 1 to 4) show a high recovery rate after surgical decompression; improvement of symptoms has been seen in approximately 95% of these cases ([@ref31]). However, animals with paraplegia and loss of pain sensation (Grade 5) exhibit a lower recovery rate, ranging from 41% to 62% ([@ref4]; [@ref31]; [@ref9]; [@ref26]; [@ref37]). Veterinarians have taken various approaches to improve postoperative recovery in Grade 5 cases, such as improvement in operative technique, introduction of high-resolution imaging modalities, and early surgical intervention. However, none of these approaches was effective enough in improving paraplegia and loss of sensation. We previously carried out autologous bone marrow mononuclear cell (BM-MNC) transplantation in dogs with acute intervertebral Grade 5 disk herniation, in which cells were injected into the subarachnoid space at the lesion site immediately after surgical manipulation, achieving postoperative recovery of motor function in 91.6% of cases ([@ref37]). Animals that have passed more than 28 days since the spinal cord injury (SCI) will have chronic SCI if they do not achieve functional recovery even after appropriate therapy ([@ref41]). These cases will suffer from permanent hind limb paraplegia and urination disorder. Development of new therapy is necessary for dogs with chronic SCI due to disk herniation.

In recent years, various types of cells have gained attention as transplants in the field of spinal cord regenerative medicine; these include Schwann cells ([@ref19]), embryonic stem cells ([@ref20]), macrophages ([@ref11]), neural stem cells ([@ref24]), olfactory ensheathing cells ([@ref1]), induced pluripotent stem cells ([@ref38]), and bone marrow stromal cells ([@ref42]). Positive results were obtained using these cells in animal experiments, whereas various issues have been raised with regard to the therapeutic approach of using cultured cells. Therapeutic use of cultured cells is still hindered by a wide range of practical issues, such as quality control of the cultured cells, potential risks of bacterial infection, concern over tumorigenesis, high cost, and the need for special equipment and techniques ([@ref22]). In addition, timely cell transplantation for spinal cord regeneration may not be possible because a relatively long time is required to grow enough cells ([@ref8]; [@ref22]; [@ref37]). Additionally, in cases where heterologous cells are used, it must be demonstrated that donor-derived cell transplants are free of pathogens, and ethical issues may also arise in obtaining transplants depending on the type of cells. On the contrary, BM-MNCs can be autotransplanted without prior culturing. Autotransplantion of BM-MNCs, which do not need culturing, has advantages in solving this problem.

In this study, we focused on this particular cell population because these can be obtained by simple centrifugation without the need for cell culture. This is the first report on the efficacy of autologous BM-MNC transplantation in dogs with chronic SCI due to disk herniation.

Materials and Methods {#sec2}
=====================

Animals
-------

Study procedures were fully explained and written informed consent based on Animal Research: Reporting *In Vivo* Experiments was obtained from the owners of all participating dogs. This trial was approved by the Aikouishida Animal Hospital Committee for Animal Experimentation.

The study enrolled 12 dogs with intervertebral disk herniation of Grade 5, which had undergone surgical intervention but did not show improvement in paraplegia or loss of pain sensation in both hind legs ([Table 1](#table1){ref-type="table"}). In this study, we defined the cases without improvement of symptoms for more than 6 months as chronic SCI. At the time of diagnosis imaging, for all dogs, rheumatoid factor (RF), antinuclear antibody, and C-reactive protein were measured using venous blood collected from the cephalic vein. As a result of having examined the following, all dogs had complete paraplegia, loss of pain sensation, and somatosensory evoked potential (SEP), and no other abnormality, except disk herniation and secondary SCI in diagnosis imaging.

Neurological examinations
-------------------------

Neurological examinations were conducted on the initial visit, immediately before surgery, and periodically after surgery. The examinations included posture response (proprioception, placing reaction, hopping reaction, and extensor postural thrust), spinal reflexes (patellar reflex, cranial tibial reflex, gastrocnemius reflex, flexion reflex, crossed extension reflex, and panniculus reflex), presence/absence of pain perception, and self-micturition ([@ref3]).

Somatosensory evoked potential
------------------------------

SEP was measured under general anesthesia with intravenous injection of 7 mg/kg propofol, followed by 1.5%--2.0% isoflurane. SEP was measured using MEB-9102 (Nihon Kohden, Tokyo, Japan) to check for functional disorders in the nervous system from the tibial nerves to the brain stem and cerebral cortex. The reference electrode was placed on the spinous process of the second cervical vertebra. Electrical stimulation was applied at a frequency of 3 Hz for 0.2 milliseconds ([@ref40]). A total of 500 responses were averaged in each session.

Diagnostic imaging
------------------

CT images were obtained on Asteion (Toshiba Medical Systems, Tokyo, Japan) using a Virtual Place Advance Lexus workstation (AZE, Tokyo, Japan), and magnetic resonance imaging (MRI) imaging was carried out using a 0.2 T Vet-MR (Esaote S.p.A, Genova, Italy).

Rheumatoid factor and antinuclear antibody measurements
-------------------------------------------------------

RF was measured using a Canine Rheumatoid Factor Test Kit (Synbiotics Corporation, Kansas City, MO).

Antinuclear antibody measurement was carried out as follows: two series of dilutions, tenfold and hundredfold serum samples were applied to the immunofluorescence assay slides (VMRD Inc., Pullman, WA) that had been smeared with cells and incubated for 30 minutes at 37°C. After washing with cleaning fluid and air-drying, the slides were incubated with a secondary antibody and IgG antibody for 30 minutes at 37°C. After washing and air-drying, the samples were observed using a fluorescence microscope.

C-reactive protein measurement
------------------------------

Laser CRP-2 (Arrows, Osaka, Japan) was used to measure the C-reactive protein level with immunonephelometry.

Collection of BM-MNCs
---------------------

BM-MNCs were collected from the proximal humerus using a bone marrow aspiration needle (16G × 2.688 inches). The collected bone marrow (5 ml) was mixed with 5 mL of heparinized saline (1,000 IU), layered on 4 ml of density gradient medium (density 1.077), and centrifuged at 450× *g* for 30 minutes. The fraction with BM-MNCs was collected and washed twice in 10 ml of physiological saline a recollected by centrifugation at 400× *g* for 5 minutes. Viable BM-MNCs were stained with trypan blue and counted using a hemacytometer. The BM-MNC transplant solution (1.1 × 10^7^ to 2.4 × 10^8^ BM-MNCs in 0.2 ml of physiological saline) was prepared as described previously ([@ref37]).

###### Clinical summary data of dogs with chronic phase spinal cord injury.

  Case   Breed                     Age (years)   Sex   Weight (kg)   Paralysis term (months)   Pre-transplantation TSCIS   Final TSCIS
  ------ ------------------------- ------------- ----- ------------- ------------------------- --------------------------- -------------
  1      Miniature Dachshund       7             M     5.8           6                         0                           14
  2      Pembroke Welsh Corgi      7             M     13.2          24                        0                           4
  3      Miniature Dachshund       7             M     4.7           18                        0                           4
  4      Miniature Dachshund       7             M     5.5           6                         0                           10
  5      Miniature Dachshund       7             F     2.9           36                        0                           4
  6      American Cocker Spaniel   4             M     10.0          12                        0                           4
  7      Miniature Dachshund       6             M     5.0           7                         0                           4
  8      Miniature Dachshund       8             M     8.0           24                        0                           0
  9      Miniature Dachshund       7.5           M     5.3           24                        0                           10
  10     Miniature Dachshund       9.5           F     3.5           72                        0                           12
  11     French Bulldog            4             M     10.3          6                         0                           0
  12     Miniature Dachshund       7             F     6.3           11                        0                           10

(TSCIS): Texas Spinal Cord Injury Scale; (M): Male; (F): Female.

BM-MNC transplantation
----------------------

Anesthesia was induced by intravenous injection of 7 mg/kg propofol, followed by 1.5%--2.0% isoflurane. After the clipping coat and disinfection, BM-MNC transplant solution (0.2 ml) was injected slowly using a 23G spinal needle into the subarachnoid space at the cisterna magna percutaneously. All animals were administered 25 mg/kg cefazolin sodium intravenously twice a day for 3 days after transplantation.

Flow cytometric analysis of BM-MNCs
-----------------------------------

To 100 μl of BM-MNC suspension in physiological saline (8.8 × 10^6^ cells/ml), FITC-labeled anti-CD14 (Serotec, Oxford, UK); anti-CD90 (Serotec); anti-CD4 (Serotec) antibodies; and anti-CD34 (Biolegend, San Diego, CA) were added, and the mixture was incubated for 30 minutes at room temperature (RT). After incubation, 900 μl of phosphate-buffered saline was added and mixed thoroughly. Cell compositions were analyzed using an Accuri C6 flow cytometer (Accuri Cytometers, Inc., Ann Arbor, MI), 100,000 events per sample. Cell viability was determined using the 7-AAD method. The number of transplanted cells is shown in [Table 2](#table2){ref-type="table"}.

Flow cytometric analysis of peripheral blood
--------------------------------------------

The relative ratios of CD3^+^ (T-cells), CD4^+^ (Helper T-cells), CD8^+^ (Cytotoxic T-cells), and CD21^+^ (B-cells) were obtained using an Accuri C6 flow cytometer against the canine-specific antibodies.

Blood samples (200 μl) were mixed with 2 μl of FACS lysis solution (Becton, Dickinson and Company, Franklin Lakes, NJ) and was incubated for 15 minutes at RT. The peripheral white blood cells (WBCs) were isolated by centrifugation (200× g) for 5 minutes at RT. The WBC fraction was rinsed before the antibodies (Serotec) were added. The samples were incubated for 15 minutes at RT, and then 2 ml of phosphate-buffered saline was added to remove the excess primary antibodies. Finally, the cells were suspended in 500 μl of FACS flow (Becton, Dickinson and Company) and kept at 4°C till analysis. The cell phenotypes of the peripheral lymphocytes were obtained by gating on the screen of forward scatter versus side scatter dot plot of FACSCalibur. For each sample, 5,000 events in the lymphocyte gates were recorded, from which the percentages of CD3^+^, CD4^+^, CD8^+^, and CD21^+^ were categorized according to their surface markers. Absolute values for lymphocyte subsets were calculated using counts obtained from WBC analysis and the flow cytometry. These procedures were conducted in accordance with [@ref37] study.

Bacterial culture and endotoxin test
------------------------------------

Endotoxin testing was carried out in accordance with the method described by [@ref32]. The mixture of 100 μl Limulus amebocyte lysate and 100 μl of BM-MNC solution was incubated for 30 minutes at 37°C. All of the transplanted samples showed an absence of endotoxin contamination. The remaining BM-MNC solution (100 μl) was cultured on trypto-soya agar medium for 7 days at 30°C.

Quantitative real-time PCR analysis of cytokines in canine BM-MNCs
------------------------------------------------------------------

Total RNA was extracted from cultured BM-MNCs using TRIzol reagent (Invitrogen) in accordance with the manufacturer's protocol and quantified using a spectrophotometer. Total RNA (1 μg) was reverse-transcribed at 42°C for 15 minutes in 20 μl with QuantiTect (Qiagen, Düsseldorf, Germany) after inactivation of reverse transcription by heating at 95°C for 3 minutes. Reverse transcription of the total RNA (1 μg) was conducted using Prime Script RT reagent (Takara, Shiga, Japan). Quantitative real-time polymerase chain reaction (PCR) reactions were carried out using an ABI 7500 Real Time PCR system Sequence Detection System (SDS, Applied Biosystems, Foster City, CA) as follows: 50°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Each reaction (20 μl) contained 2 μl template cDNA, 1 μl of each TaqMan Gene expression assays \[IL4, IL10, hepatocyte growth factor (HGF), and IL6\] (Applied Biosystems), 10 μl TaqMan Universal Master Mix II (Applied Biosystems), and 7 μl distilled water. Relative gene expression values were calculated using the comparative threshold cycle (∆∆Ct) method with the SDS 1.2 software (Applied Biosystems). This method gives the amount of target gene normalized to an 18S ribosomal RNA and was used to determine the mRNA levels of IL6. The relative expression levels were calculated using the following formula: ∆∆Ct = ∆Ct ~target\ mRNA\ level~ - ∆Ct ~IL6~, and the value of relative targeting mRNA expression was determined using the expression 2^-∆∆Ct^.

###### Phenotype of bone marrow-derived mononuclear cells.

  Case   CD4   CD8   CD14   CD29   CD34   CD90   Transplanted BM-MNCs
  ------ ----- ----- ------ ------ ------ ------ ----------------------
  1      3.4   2.6   16.7   16.6   5.6    19.6   7.5 × 10^7^
  2      3.1   2.3   24.6   11.8   4.7    27.1   3.2 × 10^7^
  3      2.2   2.9   27.9   12.1   8.6    26.1   5.2 × 10^7^
  4      2.3   2.8   29.7   11.3   7.3    22.9   5.7 × 10^8^
  5      2.1   2.4   26.6   10.4   7.9    25.5   1.1 × 10^7^
  6      2.6   2.3   27.1   10.3   9.1    23.8   1.2 × 10^8^
  7      3.7   2.1   27.6   13.8   2.6    39.3   7.2 × 10^7^
  8      3.9   2.2   26.2   12.3   2.7    36.1   1.4 × 10^8^
  9      3.1   2.8   21.2   12.9   4.7    20.8   2.9 × 10^8^
  10     2.7   2.8   22.9   11.9   5.9    27.8   2.0 × 10^8^
  11     2.2   2.9   26.7   10.1   4.3    23.9   6.4 × 10^8^
  12     2.9   2.7   19.9   15.1   4.7    27.9   1.9 × 10^8^

Values are given in percentages. (BM-MNCs): bone marrow-derived mononuclear cells.

Measurement of HGF level in the cerebrospinal fluid
---------------------------------------------------

Cerebrospinal fluid (CSF) samples were collected immediately before transplantation from all dogs and 48 hours after transplantation from three dogs. The samples were drawn from the cisterna magna in the scalps of the dogs under general anesthesia with isoflurane.

HGF protein in CSF was assayed using an enzyme-linked immunosorbent assay kit for HGF (Uscn Life Science Inc, Wuhan, China). For detection, absorbance at 450 nm was measured using a Synergy HT Multi-Detection Microplate Reader (Bio Tek, Winooski, VT).

Texas Spinal Cord Injury Scale
------------------------------

Physical and neurologic examinations of dogs were carried out every month for 6 months; the endpoint of the study was at 6 months. We also evaluated improvement in functions using the Texas Spinal Cord Injury Scale (TSCIS) ([@ref16]). This scale involves evaluation of each pelvic limb separately and has three components: gait, proprioceptive positioning, and nociception. All components were based on standard clinical neurologic examination techniques ([@ref3]). The gait scores for pelvic limbs ranged from 0 to 6: grade 0 (no voluntary movement), grade 1 (protraction with no ground clearance), grade 2 (protraction with inconsistent ground clearance), grade 3 (protraction with ground clearance in \>75% of steps), grade 4 (ambulatory with moderate paresis--ataxia), grade 5 (ambulatory with mild paresis--ataxia), and grade 6 (normal gait). Proprioceptive positioning (also referred to as knuckling) was assessed using a postural reaction test (score 0--2): score 0 (lack of a response), score 1 \[delayed response, the dog corrected the limb positions after a prolonged period (\>2 seconds)\], or score 2 (clinically normal, dogs were able to correct the limb positions immediately). Nociception was assessed using physiologic (tachycardia, tachypnea, and mydriasis) or behavioral (orientation toward the stimulus, vocalization, and licking) responses to a painful stimulus (clamping a hemostat on the distal aspect of a limb or on a nail bed of a digit): score 2 (normal nociception) or no nociception (score 0). Dogs were assigned scores of 1--10 for each pelvic limb; thus, the maximum combined limb score was 20.

Statistical analysis
--------------------

Graph Pad Prism 6 (Graph Pad software, USA) was used for statistical analysis. In three cases, paired *t*-test was used for a comparison between pre-transplant and post-transplant of the HGF concentrations in CSF. Wilcoxon signed-rank test was used for a comparison between pre-transplantation and final TSCIS scores, and the comparison of the mRNA expression in BM-MNCs in an improved group and a not improved group of final TSCIS score. *p*-values below 0.001 were considered statistically significant.

Ethical approval
----------------

This trial was approved by the Aikouishida Aminal Hospital Committee for Animal Experimentation, and the trial was carried out in accordance with the Japanese Regulations for Animal Welfare issued by The Ministry of Education, Culture, Sports, Sciences, and Technology of Japan.

Results {#sec3}
=======

This study included a total of 12 dogs: 9 male and 3 female. [Table 1](#table1){ref-type="table"} summarizes the breed, age, and body weight. Time elapsed from the onset of complete paraplegia and loss of pain sensation in the hind legs to BM-MNC transplantation was between 6 and 72 months, with a median of 15 months ([Table 1](#table1){ref-type="table"}). In neurological examinations, postural reactions were absent in all animals. Only 1 dog (Case 8) showed a lower motor neuron sign in the examination of spinal reflexes. In SEP measurement, prior to BM-MNC transplantation, no responses were detected in the hind legs of all subjects. C-reactive protein was normal in all dogs.

CT scans confirmed previous surgical interventions in the thoracolumbar region (T11--L3) in all animals. T2-weighted MRI scan confirmed signal hyperintensity in all cases. In six animals (Cases 2, 3, 5, 6, 9, and 10), T2-weighted signal hyperintensity was extensively observed along more than three vertebral bodies ([Fig. 1](#fig1){ref-type="fig"}).

In flow cytometric analysis, the transplanted BM-MNC preparations contained 2.1%--3.9% CD4 (mean ± SD: 2.85 ± 0.58), 2.1%--2.9% CD8 (mean ± SD: 2.57 ± 0.28), 16.7%--29.7% CD14 (mean ± SD: 24.76 ± 3.67), 10.1%--16.6% CD29 (mean ± SD: 12.83 ± 1.89), 2.6%--9.1% CD34 (mean ± SD: 5.68 ± 2.06), and 19.6%--39.3% CD90 (mean ± SD: 26.7 ± 5.53). The phenotype of BM-MNCs in subjects is shown in [Table 2](#table2){ref-type="table"}. Peripheral blood samples contained 70.5--87.8% CD3 (mean ± SD: 80.59 ± 4.63), 43.0%--73.9% CD4 (mean ± SD: 50.5 ± 7.75), 10.0%--29.9% CD8 (mean ± SD: 22.5 ± 5.29), 5.3%--17.9% CD21 (mean ± SD: 8.56 ± 3.25), with a CD4:CD8 ratio of 1.51:7.39 (mean ± SD: 2.55 ± 1.51). The phenotype of peripheral monocytes determined in each case is presented in [Table 3](#table3){ref-type="table"}.

The levels of mRNAs for various cytokines were measured and expressed as mean (median) of ∆∆Ct values relative to the IL-6 gene as the calibrator. ∆∆Ct values for IL-4, IL-10, and HGF mRNA expression were 7.3 (9.2), 201.8 (233.9), and 729.5 (888.2), respectively ([Table 4](#table4){ref-type="table"}). There are no significant differences in the expression of mRNAs in BM-MNCs between an improved group and an unimproved group of final TSCIS score.

![T2-weighted MRI images. (A): Case 1. (B): Case 2. (C): Case 3. (D): Case 4. (E): Case 5. (F): Case 6. (G): Case 7. (H): Case 8. (I): Case 9. (J): Case 10. (K): Case 11. (L): Case 12.](OpenVetJ-10-206-g001){#fig1}

###### Phenotype of peripheral monocytes, RF, and antinuclear antibody measurements.

  Case   CD3^+^lym   CD4^+^(CD8^-^) lym   CD8^+^(CD4^-^) lym   CD21^+^(CD3^-^) lym   CD4^+^/CD8^+^ratio   RF   ANA
  ------ ----------- -------------------- -------------------- --------------------- -------------------- ---- -----
  1      82.6        45.1                 23.3                 8.2                   1.94                 \-   \-
  2      87.8        51.9                 19.6                 6.1                   2.65                 \+   \-
  3      84.1        47.7                 24.8                 7.8                   1.92                 \-   \-
  4      81.9        49.9                 24.5                 8.9                   2.04                 \-   \-
  5      78.1        45.2                 29.9                 5.7                   1.51                 \-   \-
  6      85.7        46.8                 26.4                 8.5                   1.77                 \-   \-
  7      75.9        73.9                 10.0                 5.3                   7.39                 \+   \-
  8      70.5        55.1                 20.6                 11.5                  2.65                 \+   \-
  9      79.9        51.2                 26.7                 8.8                   1.92                 \-   \-
  10     80.1        49.8                 23.1                 6.9                   2.16                 \-   \-
  11     76.4        43.0                 15.0                 17.9                  2.86                 \+   \-
  12     84.1        46.9                 26.1                 7.1                   1.80                 \-   \-

Values are given in percentages. (lym): lymphocytes; (RF): rheumatoid factor; (ANA): antinuclear antibody.

###### mRNA expression in BM-MNCs.

  Case   IL-6 mRNA   IL-4 mRNA   IL-10 mRNA   HGF mRNA
  ------ ----------- ----------- ------------ ----------
  1      1           9.1         241.9        1098.1
  2      1           1.3         9.8          56.8
  3      1           10.7        329.7        1467.5
  4      1           12.6        362.6        987.4
  5      1           7.8         287.5        1002.6
  6      1           10.4        367.0        1320.2
  7      1           1.1         27.6         101.9
  8      1           2.3         32.0         104.5
  9      1           10.6        297.7        789.9
  10     1           11.9        189.9        898.1
  11     1           1.2         9.9          48.8
  12     1           9.2         265.9        878.2

(mRNA): ∆∆Ct; (protein): pg/ml; (BM-MNCs): bone marrow-derived mononuclear cells; (IL): interleukin; (HGF): hepatocyte growth factor.

HGF protein was detectable in pre-transplantation CSF from 8 out of 12 animals (66.6%), with a mean concentration of 15.8 pg/ml and a median of 22.3 pg/ml ([Table 5](#table5){ref-type="table"}).

HGF protein levels in CSF samples taken at 48 hours after transplantation were significantly higher than the corresponding pre-transplantation levels in all three animals examined (*p* \< 0.001). In Case 1, the HGF levels in CSF increased from 25.4 pg/ml pre-transplantation to 237.4 pg/ml post-translation. In Case 4, the HGF levels rose from 26.7 pg/ml pre-transplantation to 325.0 pg/ml post-translation. In Case 10, the levels also went up from 23.9 pg/ml pre-transplantation to 167.0 g/ml post-translation ([Table 5](#table5){ref-type="table"}).

All dogs had a pre-transplantation TSCIS score of 0. Two animals (Cases 8 and 11) did not show any improvement in their final TSCIS scores. The remaining 10 dogs (83.4%) achieved improvement in the final TSCIS scores (*p* \< 0.001). Five of them (Cases 1, 4, 9, 10, and 12; 41.7% of all subjects) regained ambulatory function with a TSCIS score greater than 10 ([Table 1](#table1){ref-type="table"}).

Discussion {#sec4}
==========

In humans, SCI affects motor and sensory functions, leading to physical impairment and significant deterioration of both life expectancy and quality of life ([@ref33]; [@ref27]). Recent advances in diagnosis and therapy have helped improve the survival rate, but patients with SCI will be disabled for their entire lives ([@ref29]). In dogs, ambulatory recovery was reported in 41%--62% of the most severe cases of thoracolumbar disk herniation (paraplegia with loss of pain sensation) after surgical decompression ([@ref4]; [@ref31], [@ref32]; [@ref26]; [@ref9]; [@ref37]). If the sensation of pain is lost for more than 2 weeks, then animals with paraplegia will rarely achieve functional recovery ([@ref14]) and will suffer from permanent hind limb paralysis, for which no curative therapy is currently available.

###### HGF protein in CSF.

  Case   Pre-transplant   Post-transplant
  ------ ---------------- -----------------
  1      25.4             237.4
  2      0                \-
  3      21.9             \-
  4      26.7             325.0
  5      19.8             \-
  6      25.9             \-
  7      0                \-
  8      0                \-
  9      22.7             \-
  10     23.9             167.0
  11     0                \-
  12     23.8             \-

(protein): pg/ml; (-): No sample; (HGF): hepatocyte growth factor; (CSF): cerebrospinal fluid.

It is known that not only do axons fail to regrow but also axonal regrowth is inhibited by scar tissue formation (gliosis) in chronic SCI ([@ref8]). Successful nerve regeneration requires replenishment of lost neurons, supplementation of various nutrition factors that stimulate axonal growth, and provision of a scaffold that allows axonal growth. Previous studies demonstrated auxiliary effects of BM-MNCs on axonal regeneration, suggesting that the cells effectively secrete various cytokines that stimulate axonal growth ([@ref45]; [@ref8]; [@ref37]). As reported previously, BM-MNC transplantation into the injured spinal cord was effective in the treatment of acute SCI in dogs ([@ref37]). BM-MNCs have also been effective in treating chronic SCIs in humans with minimal adverse events ([@ref12]), although there are no reports on the efficacy and adverse events of BM-MNC transplantation in dogs with chronic SCI.

This study is the first clinical evaluation of BM-MNC transplantation carried out in dogs with chronic SCI, which had paraplegia and loss of pain sensation due to disk herniation and failure to improve motor function after surgical decompression.

In this study, we investigated mRNA expression levels of various cytokines in BM-MNCs isolated from dogs. IL-6 was not only recognized as an inflammatory cytokine, but was also shown to protect neurons ([@ref17]). This cytokine was overexpressed after acute SCI and, as a result of its inflammatory action exceeding the neuroprotective effect, contributed to the expansion of the primary injury and generations of secondary injury ([@ref13]). On the other hand, HGF strongly inhibited apoptosis in nerve injury ([@ref39]; [@ref46]). HGF seemed to have an important role in neural regeneration because it promoted neural induction ([@ref34]; [@ref35]), induced proliferation of Schwann cells, and stimulated axonal growth ([@ref44]; [@ref43]). In addition, IL-10 was reported to suppress inflammation of the spinal cord ([@ref47]), restrict secondary injury after SCI ([@ref6]; [@ref36]), and minimize neuropathic pain after SCI ([@ref15]). IL-4 was also shown to have an anti-apoptosis effect in an injured spinal cord ([@ref21]). IL-4 prevents the onset of demyelinating myelitis and reduces the production of tumor necrosis factor α (TNFα), which is an inflammatory cytokine of the central nervous system ([@ref28]).

This study demonstrated that canine BM-MNC preparations contain higher levels of mRNAs for HGF, IL-10, and IL-4, which are known to help regenerate and protect nerves, compared to that of IL-6, which promotes secondary injury in the spinal cord. The expression levels of these cytokines varied among individuals; animals without functional recovery tended to have lower levels of HGF, IL-10, and IL-4 expressions. These results may suggest that HGF, IL-10, and IL-4 in BM-MNCs may have significant effects on the outcome of BM-MNC transplantation. In future studies, we must closely examine differences in the expression of these cytokines with regard to the animal's age, underlying diseases, and other background characteristics.

In this study, we demonstrated significant increases in HGF levels in CSF within 48 hours after autologous BM-MNC transplantation into the subarachnoid space of the spinal dura matter in three cases.

HGF stimulates nerve growth ([@ref7]; [@ref5]; [@ref18]; [@ref25]; [@ref23]), mediates angiogenesis ([@ref2]), and inhibits apoptosis ([@ref25]). All these findings indicate that HGF is a promising candidate for treating various neurological and neurodegenerative disorders. A number of studies have reported HGF variations in animal experiments. However, to the best of our knowledge, no previous studies have demonstrated elevated HGF levels in CSF in association with BN-MNC transplantation into the subarachnoid space of the spinal dura matter in dogs.

For Cases 8 and 11, there were no improvements in TSCIS score following BM-MNC transplantation. Although the reason was not clear, the degree and kind of damage to the spinal cord may be relevant because Case 8 showed lower motor neuron signs in the examination of spinal reflexes.

We analyzed only a limited number of samples and need more cases to provide definitive assessment. However, in chronic SCI in dogs, BM-MNC transplantation is likely to contribute to spinal cord regeneration via elevation of HGF levels in CSF.

This study demonstrated that spinal cord regeneration therapy by BM-MNC transplantation may be effective for at least some cases of chronic SCI, for which effective therapies are lacking. Our results suggested that multiple chemical mediators contained in heterogeneous cell population may be involved in the mode of action. Autologous BM-MNC transplantation is expected to contribute to improving quality of life of dogs that suffer from chronic SCI.
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